Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.
Maria Pia Morelli(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Victor H. Carpio, John V. Heymach(The University of Texas MD Anderson Cancer Center), Aaron Weitzman, Frances Adeyemi, Nathan Demars, Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Matthew R. Collinson-Pautz(Baylor College of Medicine), Shubham Pant(The University of Texas MD Anderson Cancer Center), Drew C. Deniger(The University of Texas MD Anderson Cancer Center), Kamisha Jernigan(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Abhishek K. Srivastava, Benny Johnson(The University of Texas MD Anderson Cancer Center)
Cited by 12
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k